[go: up one dir, main page]

WO2009113810A3 - Composition pharmaceutique, utilisation de celle-ci et procédé de traitement ou de prévention de maladies allergiques ou auto-immunes - Google Patents

Composition pharmaceutique, utilisation de celle-ci et procédé de traitement ou de prévention de maladies allergiques ou auto-immunes Download PDF

Info

Publication number
WO2009113810A3
WO2009113810A3 PCT/KR2009/001217 KR2009001217W WO2009113810A3 WO 2009113810 A3 WO2009113810 A3 WO 2009113810A3 KR 2009001217 W KR2009001217 W KR 2009001217W WO 2009113810 A3 WO2009113810 A3 WO 2009113810A3
Authority
WO
WIPO (PCT)
Prior art keywords
allergic
autoimmune diseases
pharmaceutical composition
preventing
provides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2009/001217
Other languages
English (en)
Korean (ko)
Other versions
WO2009113810A2 (fr
Inventor
전숙영
남동호
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020090019625A external-priority patent/KR100946747B1/ko
Application filed by Individual filed Critical Individual
Publication of WO2009113810A2 publication Critical patent/WO2009113810A2/fr
Publication of WO2009113810A3 publication Critical patent/WO2009113810A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une composition pharmaceutique destinée à la prévention ou au traitement de maladies allergiques ou auto-immunes, qui contient une immunoglobuline comme principe actif, isolée du sang d'un patients souffrant d'une maladie allergique ou auto-immune. Par ailleurs, l'invention concerne une autre composition pharmaceutique destinée à prévenir ou à traiter des maladies allergiques ou auto-immunes, qui contient une immunoglobuline, comme principe actif, isolée du sang d'un autre patient souffrant d'une maladie allergique ou auto-immune. La présente invention concerne aussi un procédé de fabrication et une utilisation médicinale et pharmaceutique de cette composition médicinale destinée à prévenir ou traiter des maladies allergiques ou auto-immunes. L'invention concerne aussi un procédé de prévention et de traitement de maladies allergiques ou auto-immunes, qui consiste à administrer la composition pharmaceutique à des mammifères. Par l'administration de la composition pharmaceutique de l'invention, des maladies allergiques auto-immunes contre lesquelles il est difficile de lutter avec un procédé de traitement médicamenteux standard, peuvent être traitées. Par conséquent, par cette composition pharmaceutique, l'utilisation de celle-ci pour prévenir ou traiter une maladie allergique ou auto-immune, et le procédé de prévention et de traitement utilisant cette composition, des maladies allergiques ou auto-immunes dont les symptômes ne sont pas facilement traités avec des procédés de traitement médicamenteux standards peuvent être traitées plus efficacement.
PCT/KR2009/001217 2008-03-11 2009-03-11 Composition pharmaceutique, utilisation de celle-ci et procédé de traitement ou de prévention de maladies allergiques ou auto-immunes Ceased WO2009113810A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2008-0022288 2008-03-11
KR20080022288 2008-03-11
KR1020090019625A KR100946747B1 (ko) 2008-03-11 2009-03-09 알레르기질환 및 자가면역질환의 예방 또는 치료를 위한 약학적 조성물, 그의 용도 및 알레르기질환 및 자가면역질환의 예방 또는 치료 방법
KR10-2009-0019625 2009-03-09

Publications (2)

Publication Number Publication Date
WO2009113810A2 WO2009113810A2 (fr) 2009-09-17
WO2009113810A3 true WO2009113810A3 (fr) 2009-11-26

Family

ID=41065670

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/001217 Ceased WO2009113810A2 (fr) 2008-03-11 2009-03-11 Composition pharmaceutique, utilisation de celle-ci et procédé de traitement ou de prévention de maladies allergiques ou auto-immunes

Country Status (1)

Country Link
WO (1) WO2009113810A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112638442B (zh) * 2018-06-29 2024-10-29 爱德芳世株式会社 经皮端子

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5653623A (en) * 1979-10-09 1981-05-13 Mochida Pharmaceut Co Ltd Remedy for allergic disease
JPH07133229A (ja) * 1993-11-09 1995-05-23 Fumakilla Ltd ダニアレルゲン
KR100756974B1 (ko) * 2006-03-16 2007-09-07 전숙영 알레르기 질환 및 만성염증성 질환의 치료를 위한 약학적 조성물 및 키트
KR20070095229A (ko) * 2006-03-20 2007-09-28 전숙영 알레르기 질환의 예방 또는 치료를 위한 약학적 조성물,그의 용도 및 알레르기 질환의 예방 또는 치료 방법
KR20070121217A (ko) * 2006-06-21 2007-12-27 남상윤 자가세포 파괴에 의해 야기되는 자가면역질환의 치료를위한 세포치료제 및 그 제조 방법

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5653623A (en) * 1979-10-09 1981-05-13 Mochida Pharmaceut Co Ltd Remedy for allergic disease
JPH07133229A (ja) * 1993-11-09 1995-05-23 Fumakilla Ltd ダニアレルゲン
KR100756974B1 (ko) * 2006-03-16 2007-09-07 전숙영 알레르기 질환 및 만성염증성 질환의 치료를 위한 약학적 조성물 및 키트
KR20070095229A (ko) * 2006-03-20 2007-09-28 전숙영 알레르기 질환의 예방 또는 치료를 위한 약학적 조성물,그의 용도 및 알레르기 질환의 예방 또는 치료 방법
KR20070121217A (ko) * 2006-06-21 2007-12-27 남상윤 자가세포 파괴에 의해 야기되는 자가면역질환의 치료를위한 세포치료제 및 그 제조 방법

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PITTLER, M. H. ET AL.: "Randomized, double-blind, placebo-controlled trial of autologous blood therapy for atopic dermatitis", BR. J. DERMATOL., vol. 148, no. 2, February 2003 (2003-02-01), pages 307 - 313 *
STAUBACH, P. ET AL.: "Autologous whole blood injections to patients with chronic urticaria and a positive autologous serum skin test: a placebo-controlled trial", DERMATOLOGY, vol. 212, no. 2, 2006, pages 150 - 159 *

Also Published As

Publication number Publication date
WO2009113810A2 (fr) 2009-09-17

Similar Documents

Publication Publication Date Title
HK1199726A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
PH12012501480A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
AU2012286851A8 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2007136518A3 (fr) Traitement de troubles auto-immunitaires
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
MY166890A (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2006037031A3 (fr) Formulations et procedes destines au traitement de maladies inflammatoires
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
MY157564A (en) Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
HK1202776A1 (en) Use of laquinimod for treating crohn's disease patients who failed first-line anti-tnf therapy
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
EA201492010A1 (ru) Применение высокой дозы лахинимода для лечения рассеянного склероза
MX2008013635A (es) Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos.
WO2006098603A3 (fr) Composition renfermant de l'isoorientine pour suppression d'histamine
WO2010151565A3 (fr) Multithérapies pour le traitement de l'obésité
MX2012001708A (es) Anticuerpo humanizado anti-oligomero de amiloide b.
WO2009003694A3 (fr) Procédé de traitement de maladies liées à un dysfonctionnement mitochondrial
WO2007096396A3 (fr) Procédés de traitement de maladies auto-immunes ou démyélinisantes
UA99094C2 (ru) Способ лечения пациента с системной красной волчанкой
JP2016505050A5 (fr)
WO2007081486A3 (fr) Administration orale de defensines pour traiter des maladies intestinales
WO2007056301A3 (fr) Thérapie avec un anticorps pour le traitement de maladies associées à l'intolérance au gluten
WO2009113810A3 (fr) Composition pharmaceutique, utilisation de celle-ci et procédé de traitement ou de prévention de maladies allergiques ou auto-immunes
UA109359C2 (xx) Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
WO2007070385A3 (fr) Procede therapeutique utilisant l'interferon-tau

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09720487

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09720487

Country of ref document: EP

Kind code of ref document: A2